Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.2%. By the end of trading, Regeneron Pharmaceuticals rose $4.98 (2.1%) to $237.35 on light volume. Throughout the day, 403,992 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 779,600 shares. The stock ranged in a price between $233.06-$240.22 after having opened the day at $233.84 as compared to the previous trading day's close of $232.37. Other companies within the Health Care sector that increased today were: Ambit Biosciences ( AMBI), up 25.5%, Horizon Pharma ( HZNP), up 20.8%, GW Pharmaceuticals PLC ADR ( GWPH), up 15.4% and Ocera Therapeutics ( OCRX), up 13.0%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $22.6 billion and is part of the drugs industry. Shares are up 35.8% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Mast Therapeutics ( MSTX), down 43.4%, Escalon Medical Corporation ( ESMC), down 9.3%, Spherix ( SPEX), down 7.0% and Organovo Holdings ( ONVO), down 5.8% , were all laggards within the health care sector with Santarus ( SNTS) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing